Alvotech (ALVO) Non-Current Assets (2020 - 2026)
Alvotech's (ALVO) quarterly Non-Current Assets came in at $1.0 billion in Q2 2026, up 18.02% on a YoY basis from $883.3 million in Q2 2025, and up 8.01% quarter-over-quarter from $965.2 million in Q1 2026.
Analysis
Alvotech (ALVO) Non-Current Assets (2020 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Non-Current Assets for 7 consecutive years, with $1.0 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Assets rose 18.02% year-over-year to $1.0 billion; the trailing twelve-month figure through Jun 2026 stood at $3.9 billion (up 19.72% YoY), and the FY2025 full-year result was $913.1 million, up 19.14% from the prior year.
- Non-Current Assets rose to $1.0 billion in Q2 2026 per ALVO's latest filing, from $965.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.0 billion in Q2 2026 and bottomed at $535.8 million in Q2 2022.
- Historically, Non-Current Assets has averaged $803.6 million across 5 years, with a median of $784.9 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 30.4% in 2023, then gained 1.47% in 2024.
- Over 5 years, Non-Current Assets stood at $597.7 million in 2022, then climbed by 26.36% to $755.2 million in 2023, then grew by 1.47% to $766.4 million in 2024, then advanced by 19.14% to $913.1 million in 2025, then advanced by 14.17% to $1.0 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.0 billion, $965.2 million, and $913.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 26.10 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 24.99 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 2.92 Bn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 1.83 Bn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 18.27 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 668.68 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 1.04 Bn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 1.11 Bn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 3.25 Mn |
| 10 | NutriBand | 72.57 Mn | 69.15 Mn | 181,874.00 | 2.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Bn |
| Mar 31, 2026 | 965.19 Mn |
| Dec 31, 2025 | 913.08 Mn |
| Sep 30, 2025 | 954.16 Mn |
| Jun 30, 2025 | 883.29 Mn |
| Mar 31, 2025 | 786.59 Mn |
| Dec 31, 2024 | 766.38 Mn |
| Sep 30, 2024 | 800.34 Mn |
| Jun 30, 2024 | 783.29 Mn |
| Mar 31, 2024 | 768.34 Mn |
| Dec 31, 2023 | 755.25 Mn |
| Jun 30, 2023 | 698.75 Mn |
| Dec 31, 2022 | 597.71 Mn |
| Jun 30, 2022 | 535.84 Mn |
| Dec 31, 2021 | 478.16 Mn |
| Dec 31, 2020 | 388.26 Mn |